EQS-News: Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE®
EQS-News: Formycon AG / Key word (s): Regulatory Approval Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE® ...
PharmiWeb2h
Radiation-Induced Myelosuppression Treatment Market to Reach USD 3.5 Billion by 2028 with a 3.1% of CAGR
Radiation-Induced Myelosuppression Treatment MarketThe global Radiation-Induced Myelosuppression Treatment Market is ...
centerforbiosimilars14h
3 Ustekinumab Biosimilars Launch on US Market
Three ustekinumab biosimilars enter the US market, expanding access to more affordable options referencing Stelara ...
Piper Sandler Sticks to Its Buy Rating for Teva Pharmaceutical (TEVA)
In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a ...
Lilly offers weight-loss drugs in vials at a discount to fight competition
Eli Lilly has cut the price for vials of its weight-loss drug Zepbound sold online and expanded the range of doses in an ...
PharmiWeb1h
Global Endometriosis Treatment Market to Reach USD 6,297.2 Million by 2035 at a 5.4% of CAGR
Endometriosis Treatment MarketThe global Endometriosis Treatment Market is projected to grow from USD 3,727.4 million in 2025 ...
Drug compounders sue US FDA over removal of Wegovy, Ozempic from shortage list
Drug compounders sued the U.S. Food and Drug Administration on Monday over its decision last week to remove Novo Nordisk's ...
United Therapeutics: A Unique Business With High Margins And Expansion Potential
United Therapeutics shows strong revenue growth, driven by Tyvaso, and maintains high margins and low debt burden. Read why I ...